littl mist ya initi outperform
initi coverag mist outperform rate pt intranas
etripamil pivot develop recurr unpredict rapid heart rate
condit psvt affect us repres import therapeut
advanc well mean reduc healthcar burden expens phase
result expect optimist given strong phase efficaci
adequ safeti margin well-valid pharmacolog anticip us approv
launch model us sale psvt indic
cardiovascular condit atrial fibril angina etripamil could
play meaning role also pursu share perform admir
sinc recent ipo see upsid fundament progress
fill visibl treatment gap lack reliabl mean patient
termin psvt episod impact qualiti life includ fear
occurr burden healthcar system er visit intraven
medic ablat cur opt procedur
rapid onset short durat conveni administr novel calcium channel
registr trial read event-driven phase studi
evalu time episod termin real world set etripamil
vs placebo stop analysi event attract efficacy/
safeti balanc dose level demonstr phase experi
reason predict pivot perform despit conduct
see us sale potenti psvt base uptak
address diseas popul well ablat rate
proxi project eventu prescrib assumpt three
doses/yr price impli peak sale expect
protect issu patent industri competit lack
etripamil may come serv sever cv condit phase acut rate
control atrial fibril expect begin phase poc studi
acut relief angina plan commenc project
reflect sale indic collect imput tech valu
led accomplish team well-capit leadership experienc
success develop commerci number import
pharmaceut includ sever cardiovascular categori inclus
net upsiz ipo estim current cash
provid year oper runway beyond phase top-lin result
year price histori mist
compani headquart montreal
us offic
charlott nc
develop commerci
acut treatment arrhythmia
focus
analyst certif import disclosur see disclosur
trial etripamil achiev primari endpoint
etripamil approv acut termin psvt episod
us sale achiev
posit read-out fda approv afib
posit read-out fda approv angina
us sale exceed
intranas etripamil pivot develop recurr
unpredict rapid heart rate psvt affect
us repres import therapeut advanc well
mean reduc healthcar burden expens phase
result expect optimist given
strong phase efficaci adequ safeti margin well-
valid pharmacolog anticip us launch
model us sale potenti psvt indic
cardiovascular condit atrial fibril angina also
pursu share perform admir sinc
recent ipo see upsid fundament progress
begin phase acut rate control afib
top-lin result
potenti phase data afib
begin phase acut relief angina
submit nda etripamil psvt
late potenti approv launch etripamil psvt
trial etripamil achiev statist signific
primari endpoint
etripamil fail obtain fda approv psvt
us sale fall
valu mist per share use risk-adjust discount cash flow analysi valuat obtain assign likelihood
etripamil receiv fda approv psvt achiev risk-unadjust us peak sale also imput
technolog valu assumpt includ wacc termin valu price gross margin
risk includ etripamil fail achiev phase primari endpoint safeti concern delay/prev fda approv capit need
support launch greater expect slower market adopt etripamil unexpect industri competit stock price
mist intranas etripamil pivot develop paroxysm supraventricular
tachycardia psvt repres import therapeut advanc well
mean reduc healthcar burden expens psvt recurr
unpredict rapid heart rate condit affect us alon result
on-going phase trial expect optimist given
strong phase efficaci adequ safeti margin well-valid
pharmacolog anticip us approv launch model
us sale potenti psvt indic clinic evalu cardiovascular
condit atrial fibril angina etripamil could play meaning
role plan phase result afib expect share
perform admir sinc ipo may see upsid
well-defin path commerci
lack meaning competit
typic risk associ late-stag clinic develop
small development-stag compani sale forc distribut
requir addit capit product launch achiev profit
mist led season well-qualifi team
prior mist follow earlier large-pharma career nearli year
hoffmann-la roch recent global licens ceo joseph oliveto led
chelsea therapeut late-stag develop approv northera
droxidopa neurogen orthostat hypotens noh drive sale
lorenz muller bring year industri experi commerci
strategi market role larger daiichi sankyo merck smaller exact
scienc cv compani part execut team cvt
acquist lorenz built manag
varieti key commerci capabl support ranexa launch ranolazin
psvt estim affect peopl us alon
psvt condit character sporad episod heart suddenli
without warn speed race pound qualiti believ
affect peopl us episod last anywher minut
hour frequenc occurr rang one time per year sever
episod month psvt episod may brought certain trigger
caffeine/oth stimul alcohol stress also occur unprompt
although gener lead seriou morbid increas mortal psvt
meaning impact live affect episod typic unpleas
often dysphor psvt diagnosi establish often misdiagnos
panic attack dizzi lightheaded short breath faint
ensu sign symptom disrupt depend
time place
psvt manag provid opportun
goal psvt episod end soon possibl perform
certain maneuv slow heart yield return normal rhythm
success rate low although certain medic approv acut
termin svt current standard-of-car adenosin calcium channel
blocker verapamil beta-block metoprolol also approv
given intraven requir cardiac monitor
administr henc patient commonli present emerg room often
taken ambul draw limit costli resourc untreat
spontan resolut may occur likelihood well time
unpredict may chronic take oral version drug
prophylaxi strategi unreli breakthrough episod occur
interv psvt episod omnipres threat
next one occur also patient lack confid abl quickli
unev end begun caus mani patient feel anxiou often
lead activ limit daili live exampl diagnos
patient stop drive fear faint accord one studi
cur intervent invas perman option
radiofrequ ablat despit provid high success rate ablat
appli small fraction patient due fear complic risk
need implant pacemak life less except
rare circumst patient go rf ablat schedul elect
procedur typic consid acut termin
clear need product psvt patient could discreetli
carri reliabl use termin next episod
occur
cost save could substanti time product would
reduc burden medic personnel equip facil
well-establish abil ccb verapamil readili reliabl
termin psvt episod provid start point mist develop product
profil conveni independ administr user rapid onset short
durat action could address unmet need within psvt treatment
algorithm result intranas etripamil patient deliv
meter spray one nostril lightweight handheld dispos
devic fit gener pocket handbag briefcas
top-lin phase data expect read
mist initi enrol random placebo-control
phase studi evalu etripamil vs placebo outpati
diagnos psvt follow test dose given supervis assess use
safeti episod particip given spray dispens take
along small portabl cardiac monitor upon episod believ
psvt patient connect monitor attempt termin
physic mean unsuccess etripamil use data collect
ensur episod qualifi psvt count primari
endpoint differ time termin activ control arm
enrol psvt patient us canada
random etripamil placebo respect trial event-dr
complet adjud psvt event occur sampl
size provid statist power threshold base
phase experi discuss fda conclud approv
could support efficaci singl clinic trial provid primari
endpoint contrast typic two-pivot scheme
requir mist expect report top-lin data
phase result posit support phase dose endpoint
dose-escal phase trial conduct control environ
electrophysiolog lab evalu etripamil psvt patient episod
induc trial demonstr rate convers sinu
rhythm within minut dose vs placebo
given small patient number statist result indic larg
effect post-hoc analysi relev phase design median time
convers min administr dose convert
within min wherea placebo arm convert within min
median time convers reach min etripamil gener well-
toler incid advers event dose-depend
move control set phase real world design
phase like impact efficaci demonstr note
mist conduct sever human factor studi optim oper paramet
project sale psvt
base uptak address diseas popul well
ablat rate proxi project unit eventu
prescrib per year assumpt three doses/year price impli
peak sale awar industri competit expect
protect issu patent mist world-wide right asset
oblig third parti
label expans potenti preval cardiac condit
phase acut rate control atrial fibril expect begin
phase poc studi acut relief angina plan commenc
revenu project current reflect sale indic
collect imput technolog valu
arriv price target use risk-adjust dcf analysi valuat
obtain assign likelihood etripamil receiv fda approv psvt
achiev risk-unadjust us peak sale also imput
technolog valu assumpt includ wacc termin
valu price gross margin
exhibit part
opco research differ /share individu total due round
item total /sharerisk adj estimate mist outperform
mileston pharmaceut mist late clinical-stag biopharmaceut
compani headquart montreal us offic charlott nc compani
focus develop commerci acut treatment
arrhythmia cardiac condit sole product develop self-
use intranas etripamil phase registr trial paroxysm
supraventricular tachycardia psvt revenu opportun compani
plan initi phase proof-of-concept studi follow-on indic
atrial fibril angina respectivli
psvt type rapid heartbeat start stop without warn
mist initi indic us preval condit approxim
male femal ratio diagnosi initi symptom occur
age lifelong condit seem genet basi
healthi heart sinoatri sa node locat right atrium gener
electr signal travel throughout right left atria stimul
contract signal arriv atrioventricular av node act
gate allow signal continu ventricl turn caus
contract exhibit thu rate one heartbeat regul
electr signal av node respons transfer electr
signal atria ventricl chang aforement electr
impuls affect rhythm heart caus arrhythmia paroxysm
supraventricular tachycardia psvt mist initi indic interest
exhibit electr conduct system heart
type psvt
depend underli mechan psvt typic categor av nodal
paroxysm atrial tachycardia exclud data set adjud
avnrt common form due extra piec tissu
caus signal travel av node travel back form
reentrant circuit electr current flow continu circl around av
avrt second common form also due extra piec
electr tissu howev avrt piec conduct tissu directli connect
atria ventricl allow signal flow back atria av
node establish reentrant circuit
exhibit reentrant circuit avnrt vs avrt
compani file colucci et al afp
avnrt avrt subtyp anatom differ clinic
essenti ident lead reentrant circuit exhibit caus
signal propag much higher rate normal atria
ventricl caus abnorm fast heartrat exhibit patient describ
feel one heart jump chest
exhibit signific increas heartrat psvt
praoxysm atrial tachycardia third least common subtyp psvt
also increas one heartrat differ method
avnrt anrt caus reentrant circuit atrial tachycardia ectop
pacemak exhibit ectop pacemak initi acceler electr
impuls heart perform sa node healthi patient
exhibit type abnorm conduct psvt
psvt significantli impact qualiti life
psvt regard caus addit morbid mortal
high impact qualiti life qol exampl diagnos patient
us stop drive fear faint understand symptom
start stop without warn last second minut hour
consist predict gener symptom includ rapid puls chest
pressure/pain dizzi short breath sudden fatigu anxieti faint
distinct psvt
upon initi psvt incid patient suppos attempt termin via
valsalva/vag maneuv stimul vagu nerv caus decreas
heart rate work patient frequent go hospit
receiv iv medic usual adenosin rapidli termin event
caus transient block av node importantli drug elimin
bodi less one minut treatment effect
time requir hospit administr delay termin high cost
mechan stop heart caus unpleas feel impend
death iv medic use termin psvt includ verapamil calcium
channel blocker well beta-block exhibit
patient prophylact use chronic oral antiarrhythm medic
beta blocker calcium channel blocker unfortun medic
limit use patient drug exhibit psvt episod
optim method prevent frequent use
cathet ablat essenti cure psvt success rate
greater howev fewer patient per year opt definit
treatment estim mist market research notabl cardiologist
significantli variabl estim percentag psvt patient
undergo ablat depend whether cardiologist generalist
electrophysiologist ep specialist simpl reason differ
estim ep specialist mostli see patient typic
interest ablat
cathet ablat procedur perform ep cardiologist use
radiat destroy cell respons detriment electr pathway frequent
call accessori pathway thu procedur perman stop harm
electr pathway preclud need therapeut treatment case
psvt patient cure rate especi robust risk equal
less risk mortal morbid complic
requir pacemak respect risk quit margin
invok anxieti somewhat respons low treatment rate
current miss abil patient rapidli termin psvt
episod home
address etripamil
etripamil uniqu properti stem differenti chemistri
formul packag aptar unit-dos dispos nasal-spray devic
fda previous approv drug fast onset action
short half-lif differ aris etripamil differenti chemic
etripamil new member chemic entiti fall old class l-type
calcium channel blocker includ drug verapamil
use decad treat psvt etripamil fall familiar class
similar structur verapamil optim embodi uniqu
advantag list first chemic lipophil enabl absorpt
mucosa membran therebi abil formul intranas
drug second formul provid rapid absorpt blood versu first
go gi tract third presenc ester function get
cleav blood serum esteras shortli administr exhibit caus
rapid inactiv short half-lif notabl calcium channel blocker
nearli ident structur verapamil mainli differ presenc
ether group instead rapidli metabol ester function present etripamil
exhibit overal characterist enabl etripamil use potenti
approv first self-administ medic rapid termin
pharmacolog characterist clinic support phase
studi phase studi elucid pharmacokinet pk profil
healthi patient discuss next section exhibit phase
studi demonstr half-lif approxim minut across dose
investig rel short compar sever hour half-lif calcium
channel blocker phase studi also support etripamil rapid absorpt
time maximum plasma concentr approxim eight minut
formul previous exist drug would effective/us
high concentr calcium channel sa node av node make
channel well-suit target psvt inhibit channel effect
slow impuls conduct heart muscl drug varapamil fall
class theoret effect treatment psvt episod
limit use self-administ medic due slow absorpt
long half-lif worth mention iv varapamil use in-hospit
treatment psvt episod effect iv adenosin becam
prefer treatment choic formul adenosin exist thu
known whether would good absorpt howev even
formul possibl effect would still burden associ
phase safeti pk studi laid groundwork
phase trial dose-rang studi perform healthi volunt
measur safeti pk data trial indic dose depend effect
pk pr prolong data support select four dose
phase program moreov pk data support thesi etripamil
fast onset action rapidli metabol exhibit
phase demonstr termin induc psvt
phase trial design investig efficaci etripamil
abil rapidli termin psvt episod psvt episod
unpredict studi real-world psvt episod would costli
time phase thu mist recruit patient prior diagnosi psvt
electrophysiolog ep lab induc episod patient maintain
episod five minut given etripamil trial initi enrol
patient sever subject either unabl experi episod
sustain one least five minut result patient ultim receiv
etripamil patient rel equal distribut across five studi
arm placebo exhibit primari endpoint
percentag convert normal sinu rhythm termin episod
within minut etripamil administr
convers rate placebo vs
treatment arm respect notabl three
higher dose statist signific valu arm rang
exhibit
elucid time convers mist conduct post-hoc analysi
analysi compani graph cumul convers rate dose
minut follow etripamil administr provid ad
support select dose phase trial demonstr
median time convers less three minut result
publish peer-review public jaac present exhibit
exhibit etripamil rapidli termin psvt episod phase
safeti profil exhibit phase
overal etripamil demonstr safe toler profil three
signific advers event sae experienc patient treat
sever three sae second-degre av block caus
dose measur safeti chang systol blood pressur bp
caus etripamil phase dose bp chang
transient decreas exhibit
exhibit mainten bp follow etripamil
on-going registr trial expect readout top-lin data
follow complet phase trial compani end-of-phas
meet agre design phase program conclus
mist would run one real-world trial test efficaci call
would requir use stringent valu less hit
signific primari endpoint time termin episod differ
classic requir two phase trial need hit
lenient valu less ad compon place remov
confound variabl requir adjud ecg data ensur
episod truli psvt convert sinu rhythm least
part real-world design upon onset psvt episod patient
instruct connect cardiac monitor attempt vagal maneuv
episod persist patient suppos self-administ dose
enrol psvt patient us canada
random etripamil placebo respect enrol
trial complet event exhibit
addit compani perform two open-label safeti trial
design open-label extens
node initi end recruit patient
compani file opco research
commerci opportun psvt
arriv project etripamil sale psvt two independ
approach one use peer-review market research commiss mist
base analys larg bodi longitudin us healthcar claim
data believ work repres rigor current inform
psvt patient treatment number us
market research indic overal us preval psvt
popul one-third address medic therapi
believ etripamil could reason penetr
target sale market effort high-prescrib cardiologist
estim averag annual frequenc three dose base episod rate data
approach separ methodolog also use
inform suppli mist model etripamil uptak start
estim annual us ablat rate procedur survey physician feedback
indic would expect use etripamil averag patient
everi patient undergo ablat project peak uptak
averag annual frequenc three dose
equal-weight result return blend figur etripamil unit
use year peak penetr assum unit one dose
deliv launch wac calcul peak us
sale opportun etripamil psvt
exhibit etripamil commerci opportun psvt
studi commiss mist determin year follow
psvt diagnosi total mean annual healthcar cost per-pati
repres increas
increas come er hospit inpati spend cost per
inpati admiss rang cost per er visit rang
cost per offic visit psvt account
er visits/year patient go er respons episod
ablat estim cost cur note interest
find mist research healthcar cost per-pati basi
significantli chang year follow ablat
exhibit psvt year follow diagnosi
expect phase registr trial etripamil psvt read
place potenti fda approv notabl mist retain unencumb
world-wide right ip exclus addit seven year
diagnosedcan address address peak ablations/yrdoc say theyd treat ptsfor everi one address dose per doses/pt-yrblend figur doses/yearassum peak sale opportun psvtip exclus dose per peak etripamil mileston pharmaceut
exclus grant statu nce follow submiss nda
expect compani file eu
us commerci would like perform alon compani build
commerci outsid us compani would like seek partner
addit psvt etripamil potenti demonstr clinic benefit
cardio indic manag av nodal block agent
includ atrial fibril afib angina use indic may
off-label use may follow supplementari nda
afib like secondari opportun may provid huge upsid us
preval afib arrhythmia caus disorgan electr
signal atria pass signal av node ultim
ventricl irregular rapid rate exhibit thu abil rapidli slow
impuls conduct node may offer clinic benefit met
current nodal block agent act rapidli compani plan use
phase safeti data psvt trial go straight small phase proof-of-
concept trial expect initi
cdc gov opco research
compani file opco research
compani file opco research
compani file opco research
etripamil- total revenues- y/i growth cogs- total oper oper incom oper margininterest incom net bank pre-tax incom tax net incom sale dilut gaap y/i growthdilut share cash use provid oper net cash use invest net cash provid financ net chang equival equival cash equival market total total total sharehold total liabil sharehold mileston pharmaceut
mr oliveto serv mileston presid chief execut offic
sinc march member mileston board director sinc juli
prior mileston pharmaceut mr oliveto presid ceo
director chelsea therapeut intern ltd led compani
success turnaround includ nda file fda
approv northera drug treatment neurogen orthostat
hypotens subsequ sale chelsea lundbeck inc mr oliveto
join chelsea follow two-year assign execut
advisor pappa ventur life scienc ventur capit firm
advis portfolio compani strategi govern prior pappa
ventur serv number progress senior posit across
sever oper area year career hoffmann-la roch inc
includ global allianc director roch partner organ
tenur play integr part success multipl nda
approv comprehens launch program licens transact mr
oliveto receiv ba chemistri rutger univers
dr plat serv mileston chief medic offic sinc june dr
plat bring year intern experi clinic research
work within number global pharmaceut compani prior join
mileston vice presid therapeut area head atherosclerosi
cardiovascular merck research laboratori dr plat
involv develop reposit numer cardiovascular
gemopatrilat sotalol captopril proof concept registr
approv also held posit novarti respons
global clinic trial vice presid cardiovascular clinic research
daiichi sankyo vice presid cardiovascular clinic develop
dr plat began career bristol myers-squibb occupi
sever posit respons includ medic director franc
intern group leader cardiovascular develop receiv md
univers pari board-certifi cardiologist spent
year practic medicin franc includ post-cardiovascular surgeri
intens care unit hospit mari lannelongu cardiac
rehabilit broussai hospit
mr muller serv mileston chief commerci offic sinc octob
mr muller almost year pharmaceut industri experi
serv startup-to-larg multi-national compani prior join
mileston led market team exact scienc corpor
account develop implement aspect exact scienc
market plan mr muller led thrombosi franchis daiichi
sankyo us respons launch profit loss novel
cardiovascular blood-thin drug effient prasugrel savaysa
edoxaban prior daiichi sankyo vice presid market
healthcar outcom play foundat role
transit compani compani commerci
organ oversaw launch ranexa ranolazin first-in-class
treatment chronic angina join mr muller held
variou posit sale market merck co inc includ product
manag part hypertens heart failur busi group
also serv consult arthur littl inc five year complet
technology-bas consult assign larg number biotechnolog
pharmaceut fine chemic client mr muller receiv bs
chemic engin life scienc ms chemic engin
massachusett institut technolog earn mba
harvard graduat school busi administr
philipp douvil founder cso
dr douvil mileston founder serv chief scientif offic
sinc march dr douvil member mileston board director
incept includ serv chairman
presid chief execut offic march
dr douvil year experi senior leadership posit
biopharma industri prior found mileston held posit chief
execut offic chief busi offic galileo genom later
genizon bioscienc popul genom compani co-found dr
douvil receiv phd neurosci mcgill univers later
pursu sever year post-doctor research activ univers
zurich later receiv hec univers montreal
